The cost of not using SpeciGen: Time, Money, Opportunity.

Every clinical trial sponsor has a biospecimen reconciliation line item they don’t see. It’s not on the budget. It’s not in the CRO SOW. It’s scattered across clinical teams’ time, missed samples, and change-order invoices from platform vendors and outsourced services that show up every quarter.

Add it up and it’s the largest silent cost in the study — larger than most sponsors would guess if asked. Multiply by your portfolio and it’s real money quietly leaving the room.

The costs fall into three categories your ops lead has almost certainly never added up in one place: Time. Money. Opportunity.

• Time. Scientist hours. Vendor delays. Weeks lost to tickets.
• Money. Missed samples. Change orders. Services surcharges.
• Opportunity. Submissions delayed. Questions unanswered. Science not done.

Here are the three places it goes.

You did not hire your clinical operations leaders, translational scientists, and data managers to write VLOOKUPs.

But that’s exactly what happens on most trials. EDC extract in one tab, central lab file in another, PK lab file in a third, a projected schedule copy-pasted from the protocol appendix in a fourth. Someone spends hours every week matching subject IDs, chasing visit windows, and flagging discrepancies for the CRO to answer next Tuesday.

Over a two-year study, that’s an appreciable fraction of an FTE — the FTE you hired to do assay development and method validation. That doesn’t count the frantic sprint before database lock, when the same team is doing it full-time for weeks.

And that isn’t even the real cost. The real cost is the opportunity cost: those hours weren’t spent on the questions the sponsor actually hired the team to answer.

Losing a PK sample at Cycle 1 Day 1 for one subject sounds small. It is not.

It’s a protocol deviation in the Clinical Study Report. It’s a subject who may drop out of the primary endpoint analysis. It’s a re-collection — if consent, timing, and window allow, which they usually don’t. It’s a memo to biostats. It’s the next study team meeting.

For a Phase 2 trial, one missed sample can cost more than a coordinator’s annual salary in rework and wasted enrollment. For a pivotal Phase 3 where the per-enrolled cost is already six figures, a missed sample drags timeline into the next submission window and burns quarters of commercialization runway on a molecule that was ready.

The industry pattern is not “one missed sample per study.” It’s several, discovered clustered at database lock — months after collection, when nothing is recoverable and nobody in the room can be blamed because it happened to everyone.

Continuous reconciliation catches this in the week it happens, when the coordinator can still call the site and the patient is still enrolled. The choice between “find it now” and “find it at lock” is the choice between a phone call and a six-figure incident. Same missed sample. Same data. Different discovery time.

Sponsors who moved off spreadsheets got real value from the move — whether they went to a legacy sample-tracking platform, or handed the whole thing to a CRO’s biospecimen desk, or paid a specialty vendor to run reconciliation as a service. And then they discovered the second bill.

Automated platforms and outsourced solutions in this space are priced with a modest base fee and a change order — or a services ticket — for everything the vendor has to touch. The industry pattern:

• Protocol amendments. Every amendment is a change order. Add a visit — change order. Move a PK timepoint — change order. Add a specimen type — change order. On a typical Phase 2/3 study with a handful of amendments, this is the largest single expense category most sponsors don’t see coming. Every one of them justified with the same phrase: “outside the original statement of work.”
• New sites. Adding sites during enrollment triggers per-site fees.
• New vendors. Adding a specialty genomics lab, a wearables feed, or a new pathology partner mid-study is an integration invoice or a scoping call.
• New reports. Custom views for a specific FDA question or a specific investigator: change order.
• Study extension. Extending past the planned end date: pro-rated re-billing at the current year’s list price.
• Data export. Leaving the platform or exporting to a specific statistical format: professional-services line item, quoted after you’ve already signed the renewal.

Sponsors who picked a solution on the basis of a modest base subscription — or a per-subject bundled rate from their CRO — are routinely paying a multiple of that number by year two after all the change orders. A five-times multiplier from signed base to actual annual spend is not unusual. It is the industry pattern.

The bigger problem sits underneath the invoices. Your own data isn’t really yours.

The Friday-afternoon question your coordinator has — “which samples are still at my site?” — gets answered on Monday, at best. The simple report your medical director wants for a portfolio review — “give me a subject-level list of every ADA sample with a cycle mismatch” — is a ticket. Every ticket is a queue. Every queue is days. Sometimes weeks.

You paid to have your samples tracked, and you can’t see them without asking permission. You paid to have your data reconciled, and you can’t query it without opening a case. Your own data — data your patients gave you, data your sites collected, data your labs assayed — is behind somebody else’s SLA.

The choice is not “spreadsheets vs. an automated platform.” That was the last decade’s choice. This decade’s choice is: who runs the queries — you, or somebody else’s ticketing system?

For a typical Phase 2 trial with modest amendments, add these four quietly:

• Time. Scientist FTE cost on manual reconciliation across the life of the study.
• Money. A handful of missed samples caught at database lock, at full rework cost.
• Money. Change orders and services tickets across two years, whether from a platform vendor or a CRO.
• Opportunity. Days of delay, per query, per report, per Friday, when you can’t get to your own data without asking.

The number is uncomfortable. Multiply across a portfolio and it is very uncomfortable.

The question worth asking: has your ops lead ever added those four up in one spreadsheet?

Almost nobody has. That’s how a six-figure line item hides.

SpeciGen was built on two beliefs about how modern trials actually run:

• Your trial runs continuously. Data arrives from EDC, sites, and labs at their own cadences — never in one weekly batch. Reconciliation runs against every arrival, not against the tenth-hour scramble before database lock. Missed samples surface in the week they happen, not the month before submission.
• Your protocol changes constantly. Amendments are first-class events. Adding a visit, moving a timepoint, adding a lab feed is a configuration change your data manager makes in the SpeciGen UI. Not a change order. Not a ticket. Not a services engagement.

Flat per-study pricing, regardless of how much your trial changes. Because your trial will change. That’s not a bug in your trial. That’s what modern clinical development looks like. It should not be a bug in your platform’s pricing either.

And SpeciGen is much more than tracking and reconciliation. Those are the two costs sponsors feel most painfully — the two this post is about. The platform itself runs biospecimen operations end to end: agentic AI study setup from protocol documents, sample-anchored eRequisitions with real Code128 barcodes, live kit inventory with days-of-supply projections, a site-coordinator mobile PWA with barcode scanning, discrepancy tracker with e-signatures, submission-ready eTMF closeout, and SKIA — plain-English query on your entire operational study data. Tracking and reconciliation are how SpeciGen saves you money on day one. The rest is why teams stay.